MarkForrestGordonMD

PubMed

• Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
  David Stamler, Hadas Barkay, Amanda Wilhelm, Jessica K Alexander, Nayla Chaijale, Steve Barash, Juha-Matti Savola, Samuel Frank, Karen E Anderson, Hubert H Fernandez, ...> ;Neurology and Therapy. 2024 Apr 1
• Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.
  Florian Krismer, Patrice Péran, Vincent Beliveau, Klaus Seppi, Germain Arribarat, Anne Pavy-Le Traon, Wassilios G Meissner, Alexandra Foubert-Samier, Margherita Fabbri...> ;Movement Disorders. 2024 Jan 1
• 1 citations
  Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study.
  Joseph Jankovic, Barbara Coffey, Daniel O Claassen, Joohi Jimenez-Shahed, Barry J Gertz, Elizabeth A Garofalo, David A Stamler, Maria Wieman, Juha-Matti Savola, Eran H...> ;Movement Disorders Clinical Practice. 2023 Sep 1
• 3 citations
  A PET-CT study on neuroinflammation in Huntington's disease patients participating in a randomized trial with laquinimod.
  Andreas-Antonios Roussakis, Marta Gennaro, Mark Forrest Gordon, Ralf Reilmann, Beth Borowsky, Gail Rynkowski, Nicholas P Lao-Kaim, Zoe Papoutsou, Juha-Matti Savola, Mi...> ;Brain Communications. 2023 Jan 1
• Content Validation of the Movement Disorder-Childhood Rating Scale (MD-CRS) for Dyskinetic Cerebral Palsy.
  Daniel O Claassen, Heather R Riordan, Leon S Dure, Roberta Battini, Alma Cortez, Mark Forrest Gordon, Meaghan O'Connor, Kristi Jackson, April Foster, Mark Kosinski> ;Pediatric Neurology. 2023 Apr 1
• 8 citations
  Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis.
  Florian Krismer, Klaus Seppi, Linus Jönsson, Daniel Oudin Åström, Anna-Karin Berger, Jacob Simonsen, Mark Forrest Gordon, Gregor K Wenning, Werner Poewe, > ;Movement Disorders. 2022 Jul 1
• 3 citations
  Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
  Robert A Hauser, Hadas Barkay, Amanda Wilhelm, Maria Wieman, Juha-Matti Savola, Mark Forrest Gordon> ;Parkinsonism & Related Disorders. 2022 Apr 1
• 1 citations
  Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
  Robert A Hauser, Hadas Barkay, Hubert H Fernandez, Stewart A Factor, Joohi Jimenez-Shahed, Nicholas Gross, Leslie Marinelli, Amanda Wilhelm, Jessica Alexander, Mark Fo...> ;Frontiers in Neurology. 2022 Jan 1
• 4 citations
  Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials.
  Kirsi M. Kinnunen, Ariana P. Mullin, Dorian Pustina, Emily C. Turner, Jackson Burton, Mark Forrest Gordon, Rachael I. Scahill, Emily C. Gantman, Simon Noble, Klaus Rom...> ;Frontiers in Neurology. 2021 Oct 22
• 14 citations
  Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
  Joseph Jankovic, Barbara J. Coffey, Daniel O. Claassen, Joohi Jimenez-Shahed, Barry J Gertz, Elizabeth A Garofalo, David Stamler, Maria Wieman, Juha-Matti Savola, Mark...> ;JAMA Network Open. 2021 Oct 1
• 13 citations
  Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
  Barbara J. Coffey, Joseph Jankovic, Daniel O. Claassen, Joohi Jimenez-Shahed, Barry J Gertz, Elizabeth A Garofalo, David Stamler, Maria Wieman, Juha-Matti Savola, Mark...> ;JAMA Network Open. 2021 Oct 1
• Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia.
  Martha Sajatovic, Stacy Finkbeiner, Amanda Wilhelm, Hadas Barkay, Nayla Chaijale, Nicholas Gross, Mark Forrest Gordon> ;The American Journal of Geriatric Psychiatry. 2021 Aug 16
• 24 citations
  Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET st...
  Igor D. Grachev, Philipp Meyer, Georg Becker, Marcus Bronzel, Doug Marsteller, Gina Pastino, Ole Voges, Laura Rabinovich, Helena Knebel, Franziska Zientek, Michael Rul...> ;European Journal of Nuclear Medicine and Molecular Imaging. 2021 Apr 1
• 16 citations
  Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review.
  Kirsi M. Kinnunen, Adam J. Schwarz, Emily C. Turner, Dorian Pustina, Emily C. Gantman, Mark F. Gordon, Richard Joules, Ariana P. Mullin, Rachael I. Scahill, Nellie Geo...> ;Frontiers in Neurology. 2021 Jan 1
• 11 citations
  Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
  Andrew McGarry, Peggy Auinger, Karl Kieburtz, Michal Geva, Munish Mehra, Victor Abler, Igor D. Grachev, Mark Forrest Gordon, Juha-Matti Savola, Sanjay Gandhi, Spyridon...> ;Journal of Huntington's Disease. 2020 Jan 1
• 17 citations
  Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease
  Shani Cohen, Zeev Waks, Jordan J. Elm, Mark Forrest Gordon, Igor D. Grachev, Leehee Navon-Perry, Shai Fine, Iris Grossman, Spyros Papapetropoulos, Juha-Matti Savola> ;BMC Medical Informatics and Decision Making. 2018 Dec 20
• 109 citations
  Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.
  Willemijn J. Jansen, Rik Ossenkoppele, Betty M. Tijms, Anne M. Fagan, Oskar Hansson, William E. Klunk, Wiesje M. van der Flier, Victor L. Villemagne, Giovanni B. Friso...> ;JAMA Psychiatry. 2018 Jan 1
• 26 citations
  Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem.
  Stephen P. Arneric, Jesse M. Cedarbaum, Sean Khozin, Spyros Papapetropoulos, Derek L. G. Hill, Michael T. Ropacki, Jane Rhodes, Penny A. Dacks, Lynn D. Hudson, Mark Fo...> ;Nature Reviews. Drug Discovery. 2017 Sep 22
• 3 citations
  Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson's Disease.
  William Seiple, Danna Jennings, Richard B Rosen, Leona Borchert, Lee Canale, Nora M. Fagan, Mark Forrest Gordon> ;Parkinson's Disease. 2016 Dec 18
• Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarke...
  Arnerić SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L, Dean R, Engelborghs S, Genius J, Gordon MF, Hitchcock J, Kaplow J, Luthman J, Meibach R, Raun...> ;J. Alzheimers Dis.. 2016-11-01
• Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation.
  Haas M, Stephenson D, Romero K, Gordon MF, Zach N, Geerts H> ;Alzheimers Dement. 2016-09-01
• Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge.
  Geerts H, Dacks PA, Devanarayan V, Haas M, Khachaturian ZS, Gordon MF, Maudsley S, Romero K, Stephenson D> ;Alzheimers Dement. 2016-09-01
• 19 citations
  Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairme...
  Mark Forrest Gordon, William R. Lenderking, Amy Duhig, Julie Chandler, J. Jason Lundy, David S. Miller, Elisabeth Piault-Louis, Rachelle S. Doody, Douglas Galasko, Ser...> ;Alzheimer's & Dementia. 2016 Jan 1
• 22 citations
  Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease
  Diane Stephenson, Michele T.M. Hu, Klaus Romero, Kieran Breen, Davide Burn, Yoav Ben-Shlomo, Atul Bhattaram, Maria Isaac, Charles S. Venuto, Ken Kubota, Max A. Little,...> ;Journal of Parkinson's Disease. 2015 Jan 1
• Age-Stratified Prevalence of Mild Cognitive Impairment and Dementia in European Populations: A Systematic Review.
  Alexander M, Perera G, Ford L, Arrighi HM, Foskett N, Debove C, Novak G, Gordon MF> ;J. Alzheimers Dis.. 2015-01-01
• Join now to see all